Video

Weighing Safety Risks and Efficacy of New Vitrectomy Procedure Option

Author(s):

As with all new technologies for surgical procedures, there will be questions to be answered about the safety for hypersonic vitrectomy. While human trials have not started yet, there are good indications in cadaveric and animal studies.

As with all new technologies for surgical procedures there will be questions to be answered about the safety for hypersonic vitrectomy. While human trials have not started yet there are good indications in cadaveric and animal studies.

Speaking at the annual meeting of the American Academy of Ophthalmology in Chicago, Paulo E. Stanga, MD, from the Manchester Royal Eye Hospital, said the procedure he has helped develop "is as effective as the commercially available guillotine technology in removing the vitreous." Stanga said if human trials go well the technology should be available to surgeons at some point in 2017.

Related Videos
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Joel A. Pearlman, MD, PhD: Phase 2a Data on Oral RZ402 for DME | Image Credit: Retina Consultants Medical Group
Roger A. Goldberg, MD: Pooled Visual Function Data of NT-501 for MacTel | Image Credit: Bay Area Retina Associates
© 2024 MJH Life Sciences

All rights reserved.